Stock Code: 300677 Stock Abbreviation: INOVPharmaceutical Announcement No.: 2026-022
Announcement on Seeking Shareholder Authorization for the Board of Directors to Decide on the 2026 Interim Dividend Plan
The Company and all members of the Board of Directors guarantee the truthfulness, accuracy, and completeness of the information disclosed in this announcement, and that there are no false records, misleading statements, or material omissions.
INOVPharmaceutical Co., Ltd. (hereinafter referred to as the "Company") held its Fourth Board of Directors' Fourteenth (Regular) Meeting on April 23, 2026, and reviewed and approved the "Proposal on Seeking Shareholder Authorization for the Board of Directors to Decide on the 2026 Interim Dividend Plan." In accordance with the "Guiding Opinions on Regulating the Cash Dividend Payouts of Listed Companies No. 3," the "Articles of Association of INOVPharmaceutical Co., Ltd." (hereinafter referred to as the "Articles of Association"), and other relevant regulations, in order to implement the normalized cash dividend mechanism for listed companies, improve investor returns, and in conjunction with the Company's actual situation, the Board of Directors proposes to seek shareholder authorization for the Board of Directors to formulate the 2026 interim dividend plan. This proposal still needs to be submitted for review at the Company's 2025 Annual General Meeting of Shareholders.
The relevant matters are hereby announced as follows:
I. 2026 Interim Dividend Arrangement
- Conditions for Interim Dividend